What is Prestige Consumer Healthcare EV-to-EBITDA?
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Prestige Consumer Healthcare's enterprise value is $4,686 Mil.
Prestige Consumer Healthcare's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $11 Mil. Therefore, Prestige Consumer Healthcare's EV-to-EBITDA for today is 435.82.
The historical rank and industry rank for Prestige Consumer Healthcare's EV-to-EBITDA or its related term are showing as below:
PBH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.78 Med: 15.15 Max: 640.45
Current: 435.82
During the past 13 years, the highest EV-to-EBITDA of Prestige Consumer Healthcare was 640.45. The lowest was 9.78. And the median was 15.15.
PBH's EV-to-EBITDA is ranked worse than 99.58% of 708
companies
in the Drug Manufacturers industry
Industry Median: 13.88
vs PBH: 435.82
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), Prestige Consumer Healthcare's stock price is $70.13.
Prestige Consumer Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.640. Therefore, Prestige Consumer Healthcare's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Prestige Consumer Healthcare EV-to-EBITDA Historical Data
The historical data trend for Prestige Consumer Healthcare's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Prestige Consumer Healthcare's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's EV-to-EBITDA falls into.
Prestige Consumer Healthcare's current Enterprise Value is $4,686 Mil.
Prestige Consumer Healthcare's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Prestige Consumer Healthcare's PE Ratio for today is calculated as:
Prestige Consumer Healthcare's share price for today is $70.13.
Prestige Consumer Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.640.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Prestige Consumer Healthcare EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Prestige Consumer Healthcare's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Prestige Consumer Healthcare (Prestige Consumer Healthcare) Business Description
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PBH has been successfully added to your 